Through this acquisition, Pacrim and its subsidiary, Alponics SA, now span the full value chain — from genetic development and cultivation to Swiss GMP‑certified processing, batch release, and pharmaceutical-grade packaging.

This transaction consolidates a rare model of Swiss vertical integration, combining Bio‑Suisse and GACP cultivation, Swissmedic licensing, international business and direct access to Swiss pharmacy channels under one unified group.

The leadership teams of both companies commented:

“We are extremely proud that the two companies have joined forces to deliver a truly integrated Swiss medicinal flower solution.  The combined companies now offer licensing for controlled-substance cultivation under Swiss narcotic regulations (high-THC medicinal varieties), Bio‑Suisse certification and the assurance of Swiss GMP standards to our customers.”

Dr. Claudia Zieres‑Nauth, CEO of Medropharm AG, added:

“After a long process of identifying the right strategic partner for Medropharm’s ongoing development, we are very pleased to have agreed terms with the Pacrim Group. Together, we deliver to the industry a trusted, reliable, quality‑driven partner with a clear long‑term vision.”

Medropharm AG is widely recognized as a Swiss pioneer in pharmaceutical-grade cannabis and cannabinoid-based medicinal products. It holds:

• A Swissmedic GMP/GDP operating license and narcotic license for pharmaceutical products, specialized in medicinal cannabis
• In-house medical logistics and storage
• Licensing and documented capability in extraction, short‑path distillation, and GMP processing of cannabinoid-based pharmaceutical products
• The operational ability to perform batch release, enabling direct supply of products to Swiss pharmacies under Swiss regulatory control (Swiss ID / controlled substance licenses)

These licenses and capabilities allow Medropharm to place finished medicinal cannabis products directly into the Swiss pharmacy channel, strengthening its Swiss-first supply certainty.

Alponics SA, now fully integrated under Pacrim, complements this pharmaceutical backbone with cultivation and compliance credentials including:

• Bio‑Suisse organic certification, demonstrating high ecological and purity standards
• GACP compliance for cultivation and harvesting procedures
• ISO 9001:2015 quality management systems, ensuring process consistency and traceability
• Licensing for high‑THC medicinal production under Swiss narcotic regulations

With these credentials, Alponics provides a secure, high-quality Swiss cultivation platform under full ownership, ensuring seamless integration from plant to packaged flower under the strict control regime required for regulated pharmaceutical markets.

Core Values: Swiss  Quality, Integrity & Supply Certainty

• Swiss Core: All key processes — from genetics and cultivation to extraction, quality control, formulation, and packaging — are based in Switzerland, under Swiss regulatory oversight. Medropharm emphasizes delivering 100% Swiss quality.
• Quality: The group operates according to the highest standards — GACP, GDP, and GMP processing.
• Integrity: With full traceability, documented quality systems, and regulated licensing for controlled substances, the group offers reliability and transparency to regulators, physicians, pharmacies, and patients.
• Certainty: Because Medropharm holds batch release capability and Swiss regulatory licenses, this integrated entity can reliably deliver medicinal cannabis products into Swiss pharmacies — reducing intermediaries and regulatory risk.

By aligning cultivation, GMP processing, regulatory, GDP wholesale, and market access functions under one group, Pacrim and Medropharm provide unmatched supply certainty, Swiss regulatory integrity, and a fully Swiss-controlled medicinal cannabis value chain.

Strategic Outlook & International Ambition

With integration completed, the group will now accelerate entry into key regulated markets including Germany, the United Kingdom and Australia, leveraging Medropharm’s established Medrofarm‑FLOWERS and Medrofarm‑SEEDS lines, built under Swissmedic and GMP regimes. New pipelines will emphasize higher performance, therapeutic precision, and regulatory-first standards.

If you have any questions or other concerns, our specialist staff will be happy to assist you: info@medropharm.ch